The study presents, for the first time, the results of a grant won by competition in 2006 and achieved by combined efforts of three centers of scientific research from Iasi: the University of Medicine and Pharmacy „Gr T. Popa”, the Technical University „Gh. Asachi” and the Institute of Macromolecular Chemistry „Petru Poni”. An inovative treatment which synergistically combines compressive therapy with a controlled release of topical flebotropic substances, using nanotechnology methods was suggested for chronic venous disease (CVD).

Material and method

The research was based, initially, on conceiving and study of two biopolymers, and then of two biomaterials, which integrates physically or links chemically active therapeutic principles for CVD, in order to deliver them in a controlled and unaltered manner to cutaneous venous vascular endothelium. Afterwards, the research concentrated on „in vitro” and “in vivo” studies on animals in order to select the best solution from the two biomaterials.

Of the 42 subjects of the study, only 29 remain for the final visit. They were divided into three categories: subgroup I.1 – 5 patients who took the treatment with the sock 2, coated with chemically linked troxerutin, subgroup I.2 - 10 patients who followed the treatment with the sock 2 without being soaked (but with technical parameters readjusted) and group II - 14 patients who followed treatment with the sock 1, with an elastic contention.

Results and conclusions

It was demonstrated that the biomaterial I was able to capture the troxerutin chemically linked to biopolymer I and then deliver it in a controlled manner.

The therapy suggested by us – the use of a sock 2, with elastic contention, soaked in chemically linked troxerutin, is superior to all alternative treatments and it is basically without any adverse effects - either subjectively declared by the patient or objectively observed trough anatomo-pathological exam of skin biopsies effectuated on the researched animals.